Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 350 of 1048 entries
View as:

A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT05359393 Org: User:
Start: 12/01/22 End: 09/01/27 Due: 09/01/28

Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.

Phase: N/A Priority: Normal
NCT ID: NCT05142709 Org: User:
Start: 10/31/21 End: 12/31/24 Due: 12/31/25

wXELIRI Versus FOLFIRI Regimen in the Treatment of Advanced Colorectal Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT01736904 Org: User:
Start: 05/31/12 End: 12/31/15 Due: 12/31/16

Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

Phase: N/A Priority: Normal
NCT ID: NCT05982834 Org: User:
Start: 05/09/23 End: 12/31/25 Due: 12/31/26

Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage Ⅲ Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00816855 Org: User:
Start: 02/28/07 End: 06/30/10 Due: 06/30/11

The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)

Phase: N/A Priority: Normal
NCT ID: NCT04517227 Org: User:
Start: 07/31/21 End: 10/31/25 Due: 10/31/26

Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT05316480 Org: User:
Start: 05/01/22 End: 12/30/26 Due: 12/30/27

Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study

Phase: N/A Priority: Normal
NCT ID: NCT04913571 Org: User:
Start: 05/27/21 End: 06/01/23 Due: 06/01/24

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05759546 Org: User:
Start: 02/01/23 End: 06/01/27 Due: 06/01/28

Circulating EV Long RNA Profiles in SCLC

Phase: N/A Priority: Normal
NCT ID: NCT05191849 Org: User:
Start: 10/25/21 End: 10/25/24 Due: 10/25/25

A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)

Phase: N/A Priority: Normal
NCT ID: NCT05999149 Org: User:
Start: 08/20/23 End: 08/30/27 Due: 08/30/28

Neoadjuvant SNF Precision Therapy Phase III

Phase: N/A Priority: Normal
NCT ID: NCT06913777 Org: User:
Start: 04/08/25 End: 04/15/27 Due: 04/15/28

Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05371301 Org: User:
Start: 07/16/21 End: 12/31/23 Due: 12/31/24

Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01102335 Org: User:
Start: 04/30/10 End: 12/31/12 Due: 12/31/13

Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy

Phase: N/A Priority: Normal
NCT ID: NCT06187740 Org: User:
Start: 12/01/23 End: 12/31/25 Due: 12/31/26

Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06613633 Org: User:
Start: 09/01/18 End: 09/20/24 Due: 09/20/25

Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT07041437 Org: User:
Start: 06/30/25 End: 01/31/27 Due: 01/31/28

Sarcopenia and Peripheral Artery Disease With Chronic Limb Threatening Ischemia

Phase: N/A Priority: Normal
NCT ID: NCT07037979 Org: User:
Start: 01/01/23 End: 12/31/24 Due: 12/31/25

Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT05451719 Org: User:
Start: 07/31/22 End: 07/31/25 Due: 07/31/26

The Prediction Model of Avastin Plus Chemotherapy in Unresectable Ras Mutant CRLM Patients

Phase: N/A Priority: Normal
NCT ID: NCT04525313 Org: User:
Start: 08/31/20 End: 12/31/22 Due: 12/31/23

Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT05839288 Org: User:
Start: 11/01/22 End: 04/01/23 Due: 04/01/24

mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06149689 Org: User:
Start: 01/10/24 End: 10/31/26 Due: 10/31/27

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05438706 Org: User:
Start: 07/10/22 End: 07/10/24 Due: 07/10/25

Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05095636 Org: User:
Start: 03/17/21 End: 09/30/23 Due: 09/30/24

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)

Phase: N/A Priority: Normal
NCT ID: NCT01287624 Org: User:
Start: 01/31/11 End: 03/31/14 Due: 03/31/15